Home > > Global Antimicrobial Susceptibility Testing Market Report
The Antimicrobial Susceptibility Testing market was valued at $3,342.4 Million in 2022, and is projected to reach $5,865.4 Million by 2032 growing at a CAGR of 5.85% from 2023 to 2032.Antimicrobial susceptibility testing is a laboratory technique used to determine the ability of antimicrobial agents to inhibit the growth of microorganisms, such as bacteria and fungi. This testing is important in the treatment of infections caused by these microorganisms, as it helps to identify the most effective antimicrobial agent for a particular infection. The global antimicrobial susceptibility testing market is driven by factors such as the increasing prevalence of infectious diseases, the growing demand for rapid and accurate diagnostic methods, and the increasing adoption of advanced technologies for antimicrobial susceptibility testing. Opportunities for growth in the antimicrobial susceptibility testing market include the development of new and innovative testing methods, the expansion of healthcare infrastructure in developing countries, and the increasing adoption of personalized medicine approaches to the treatment of infectious diseases. Trends in the antimicrobial susceptibility testing market include the increasing use of automation and technology in testing processes, the growing demand for rapid and point-of-care testing, and the development of new and emerging antimicrobial agents. Top companies in the antimicrobial susceptibility testing market include BD, bioMérieux, Thermo Fisher Scientific, Agilent Technologies, and Microscan. These companies have made significant developments in the market, including the introduction of new and innovative testing methods and the development of advanced technologies for antimicrobial susceptibility testing.